Lyophilized orally disintegrating tablet formulations of d-lysergic acid diethylamide for therapeutic applications
A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.
1. An LSD tablet prepared by lyophilization of a stock solution in a pre-formed mold, wherein the stock solution consists essentially of:
a non-gelling matrix former of maltodextrin at 2-10% weight percent, a binder of hydroxypropyl methylcellulose at 1-5% weight percent, a filler chosen from the group consisting of mannitol at 2-10% weight percent and trehalose at 2-10% weight percent, LSD tartrate present at less than 1% weight percent, and water; wherein
the LSD tablet is capable of disintegrating within 60 seconds.
2. A method of making an LSD tablet from a stock solution, wherein the stock solution consists essentially of:
a non-gelling matrix former of maltodextrin at 2-10% weight percent, a binder of hydroxypropyl methylcellulose at 1-5% weight percent, a filler chosen from the group consisting of mannitol at 2-10% weight percent and trehalose at 2-10% weight percent, LSD tartrate present at less than 1% weight percent, and water;
including the steps of:
flash freezing the stock solution in a pre-formed mold;
lyophilizing the flash frozen stock solution in the pre-formed mold;
and forming an orally disintegrating tablet capable of rapidly disintegrating in less than 60 seconds.
3. The method of claim 2 , wherein the stock solution further comprises a buffer chosen from the group consisting of citrate, phosphate, and acetate.
4. A method of treating an individual in need thereof with LSD comprising administering an LSD tablet prepared by lyophilization of a stock solution in a pre-formed mold, wherein the stock solution consists essentially of:
a non-gelling matrix former of maltodextrin at 2-10% weight percent, a binder of hydroxypropyl methylcellulose at 1-5% weight percent, a filler chosen from the group consisting of mannitol at 2-10% weight percent and trehalose at 2-10% weight percent, LSD tartrate present at less than 1% weight percent, and water; wherein
the LSD tablet is capable of disintegrating within 60 seconds;
and treating the individual.
5. The method of claim 4 , wherein the individual has trouble swallowing, is elderly, or has dementia.
6. The method of claim 4 , wherein said treating step is further defined as treating a condition or disease chosen from the group consisting of anxiety disorders, depression, headache disorder, obsessive compulsive disorder (OCD), personality disorders, stress disorders, drug disorders, gambling disorder, eating disorders, body dysmorphic disorder, pain, neurodegenerative disorders, autism spectrum disorder, and neurological disorders.
7. The method of claim 4 , wherein said administering step is further defined as administering 0.01-1 mg of LSD.